Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.

Published on Sep 30, 2021in Diabetes Care19.112
· DOI :10.2337/DC21-1081
Hajime Nagasu13
Estimated H-index: 13
(Kawasaki Medical School),
Yuichiro Yano68
Estimated H-index: 68
(Duke University)
+ 30 AuthorsJun Wada64
Estimated H-index: 64
(Okayama University)
OBJECTIVE null Randomized controlled trials have shown kidney-protective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown. null RESEARCH DESIGN AND METHODS null Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease. null RESULTS null At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m2, and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m2 per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26–0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (Pheterogeneity ≥ 0.35). null CONCLUSIONS null The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.
📖 Papers frequently viewed together
#1Qiuhe JiH-Index: 24
#2Linong Ji (PKU: Peking University)H-Index: 53
Last. Odd Erik Johansen (Boehringer Ingelheim)H-Index: 30
view all 12 authors...
We investigated whether the cardiorenal benefits of the sodium-glucose co-transporter-2 inhibitor empagliflozin were affected by body mass index (BMI) in the EMPA-REG OUTCOME trial in type 2 diabetes patients with established cardiovascular disease, which included Asians. In this exploratory analysis, we used Cox regression to evaluate the effects of empagliflozin on all-cause mortality, hospitalization for heart failure (HHF) or CV death, and incident or worsening nephropathy by baseline BMI ca...
#1Ralph A. DeFronzo (University of Texas at Austin)H-Index: 181
#2W. Brian Reeves (University of Texas at Austin)H-Index: 31
Last. Alaa S. Awad (University of Texas at Austin)H-Index: 21
view all 3 authors...
Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike other complications of diabetes, the prevalence of diabetic kidney disease has failed to decline over the past 30 years. Hyperglycaemia is the primary aetiological factor responsible for the development of diabetic kidney disease. Once hyperglycaemia becomes established, multiple pathophysiological disturbances, including...
#7Johannes F.E. Mann (UG: University of Groningen)H-Index: 66
#8John J. V. McMurray (UG: University of Groningen)H-Index: 1
Abstract Background Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or...
#1Simke W. WaijerH-Index: 3
#2Di Xie (Southern Medical University)H-Index: 1
Last. Hiddo J.L. HeerspinkH-Index: 74
view all 10 authors...
Background Early reduction in albuminuria with an SGLT2 (sodium-glucose cotransporter 2) inhibitor may be a positive indicator of long-term cardiovascular and renal benefits. We assessed changes in albuminuria during the first 12 weeks of treatment and subsequent long-term cardiovascular and renal risks associated with the SGLT2 inhibitor, empagliflozin, in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) trial. Methods and Results We c...
#1Kengo Furuichi (Kanazawa Medical University)H-Index: 6
#2Miho Shimizu (Kanazawa University)H-Index: 21
Last. Takashi Wada (Kanazawa University)H-Index: 64
view all 25 authors...
Introduction The speed of declining kidney function differs among patients with diabetic nephropathy. This study was undertaken to clarify clinical and pathological features that affect the speed of declining kidney function in patients with diabetic nephropathy. Research design and methods This study was design as multicenter retrospective study. The subjects (377 patients with diabetic nephropathy diagnosed by kidney biopsy at 13 centers in Japan) were classified into three groups based on the...
#1Naoki Nakagawa (Asahikawa Medical University)H-Index: 14
#2Tadashi Sofue (Kagawa University)H-Index: 11
Last. Naoki Kashihara (Kawasaki Medical School)H-Index: 43
view all 25 authors...
The Japan Chronic Kidney Disease (CKD) Database (J-CKD-DB) is a large-scale, nation-wide registry based on electronic health record (EHR) data from participating university hospitals. Using a standardized exchangeable information storage, the J-CKD-DB succeeded to efficiently collect clinical data of CKD patients across hospitals despite their different EHR systems. CKD was defined as dipstick proteinuria ≥1+ and/or estimated glomerular filtration rate <60 mL/min/1.73 m2 base on both out- and in...
#1Björn Pasternak (KI: Karolinska Institutet)H-Index: 34
#2Viktor Wintzell (KI: Karolinska Institutet)H-Index: 7
Last. Peter Ueda (KI: Karolinska Institutet)H-Index: 27
view all 11 authors...
Abstract Objective To assess the association between use of sodium-glucose co-transporter 2 (SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice. Design Cohort study using an active comparator, new user design and nationwide register data. Setting Sweden, Denmark, and Norway, 2013-18. Participants Cohort of 29 887 new users of SGLT2 inhibitors (follow-up time: dapagliflozin 66.1%; empagliflozin 32.6%; canagliflozin 1.3%) and 29 887 new users of an active com...
#1Hiddo J.L. Heerspink (The George Institute for Global Health)H-Index: 74
#2Avraham Karasik (TAU: Tel Aviv University)H-Index: 40
Last. Mikhail Kosiborod (UMKC: University of Missouri–Kansas City)H-Index: 67
view all 17 authors...
Summary Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with type 2 diabetes with or without chronic kidney disease. The aim of this study was to assess whether these benefits extend to patients with type 2 diabetes treated in routine clinical practice. Methods CVD-REAL 3 was a multinational observational cohort study in which new users of SGLT2 inhibitors and other gluco...
#1Shinji Kume (Shiga University of Medical Science)H-Index: 37
#2Shin-ichi Araki (Shiga University of Medical Science)H-Index: 46
Last. Hiroshi Maegawa (Shiga University of Medical Science)H-Index: 71
view all 9 authors...
AIMS/INTRODUCTION: Diabetic kidney disease is characterized by increased albuminuria and/or a reduced glomerular filtration rate (GFR). We analyzed secular changes in the prevalence of albuminuria and reduced estimated GFR (eGFR) in Japanese patients with type 2 diabetes, and identified factors associated with these changes. MATERIALS AND METHODS: Using 1996, 2001, 2006 and 2014 cohort data from the Japanese serial cross-sectional studies conducted at Shiga University of Medical Science, secular...
#1Vlado Perkovic (UNSW: University of New South Wales)H-Index: 94
#2Meg Jardine (UNSW: University of New South Wales)H-Index: 47
Last. Kenneth W. MahaffeyH-Index: 117
view all 24 authors...
Abstract Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium...
Cited By0
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.